Children’s Hospital GME Support Reauthorization Act of 2023

Bill: 118-hr-3887
Sponsor: full_name: Rep. Crenshaw, Dan [R-TX-2]
Introduced: 2023-06-07
Policy area: Health
Subjects: Child health

Health programs administration and funding

Higher education

Hospital care

Medical education

Sex, gender, sexual orientation discrimination
Latest action: action_date: 2024-11-20
text: Placed on the Union Calendar, Calendar No. 629.

Summaries:
action_date: 2023-06-07
action_desc: Introduced in House
text: <html><body><p><b>Children's Hospital GME Support Reauthorization Act of 2023</b></p> <p>This bill reauthorizes through FY2028 the Children's Hospital Graduate Medical Education Payment program, which supports education and training for medical residents and fellows in children's hospitals. The bill also bars children's hospitals that provide gender-affirming care to minors from receiving payments through the program.</p> <p>Under the bill, gender-affirming care generally includes procedures (e.g., surgeries or hormone therapies) that change the body of an individual to correspond to a sex that is different than the individual's biological sex. It excludes, however, specified types of procedures, including those for treating (1) individuals who have both ovarian and testicular tissue or abnormal sex chromosome structure or hormones, or (2) infections or other harms that result from a previous gender-transition procedure.</p></body></html>

tv_txt: IB Union Calendar No. 629 118th CONGRESS 2d Session H. R. 3887 [Report No. 118–758] IN THE HOUSE OF REPRESENTATIVES June 7, 2023 Mr. Crenshaw introduced the following bill; which was referred to the Committee on Energy and Commerce November 20, 2024 Additional sponsors: Mr. Johnson of Ohio , Mrs. Miller-Meeks , Mrs. Harshbarger , Mr. Pfluger , Mr. Babin , Mr. Self , Mrs. Miller of West Virginia , Ms. Tenney , Mr. Santos , Mr. Van Drew , Mr. Grothman , Mr. Scott Franklin of Florida , Mr. Gaetz , Mr. Nehls , Mrs. Cammack , Mr. Stauber , Mr. Williams of Texas , Mr. Arrington , Mr. Mann , Mr. Norman , Mr. Posey , Mr. Steube , Mr. Ellzey , Mr. Carter of Georgia , Mr. Green of Tennessee , Mr. Jackson of Texas , Mr. Mooney , Mr. Duncan , Mrs. Miller of Illinois , Mr. Moran , Mr. Finstad , and Mr. Rouzer November 20, 2024 Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed Strike out all after the enacting clause and insert the part printed in italic For text of introduced bill, see copy of bill as introduced on June 7, 2023 A BILL To amend title III of the Public Health Service Act to reauthorize the program of payments to children’s hospitals that operate graduate medical education programs, and for other purposes.

1. Short title This Act may be cited as the Children’s Hospital GME Support Reauthorization Act of 2023 . 2. Program of payments to children's hospitals that operate graduate medical education programs Section 340E of the Public Health Service Act ( 42 U.S.C. 256e ) is amended— (1) in subsection (a), by striking 2023 and inserting 2028 ; (2) in subsection (b)(3)(D), by inserting and the end of fiscal year 2028, after fiscal year 2022, ; (3) in subsection (e), by adding at the end the following new paragraph: (4) Prohibition on payments to hospitals furnishing specified procedures and drugs to minors (A) In general Notwithstanding any other provision of this section, no payment may be made under this section to a children’s hospital for a fiscal year (beginning with fiscal year 2024) if, at any point during the preceding fiscal year, such hospital furnished specified procedures and drugs (as defined in subsection (g)) to an individual under 18 years of age. (B) Special rule for fiscal year 2024 In applying subparagraph (A) with respect to payments described in such subparagraph for fiscal year 2024— (i) the reference to for a fiscal year shall be treated as a reference to for any portion of fiscal year 2024 occurring after December 31, 2023 ; and (ii) the reference to the preceding fiscal year shall be treated as a reference to the period beginning on September 1, 2023, and ending on December 31, 2023 . (C) Rule of construction Nothing in this paragraph shall be construed as prohibiting payments for a fiscal year (or, in the case of payments for fiscal year 2024, during the portion of such fiscal year described in subparagraph (B)(i)) to a hospital that, during the preceding fiscal year (or, in the case of payments for fiscal year 2024, during the period described in subparagraph (B)(ii)), furnished mental or behavioral health services to individuals under 18 years of age for the treatment of gender dysphoria not consisting of specified procedures and drugs. ; (4) in subsection (f)— (A) in paragraph (1)(A)— (i) in clause (v), by striking and at the end; (ii) in clause (vi), by striking the period at the end and inserting ; and ; and (iii) by adding at the end the following: (vii) for each of fiscal years 2024 through 2028, $124,000,000. ; and (B) in paragraph (2)— (i) in subparagraph (E), by striking and at the end; (ii) in subparagraph (F), by striking the period at the end and inserting ; and ; and (iii) by adding at the end the following: (G) for each of fiscal years 2024 through 2028, $261,000,000. ; and (5) in subsection (g), by adding at the end the following new paragraph: (4) Specified procedures and drugs (A) In general Except as provided in subparagraph (B), the term specified procedures and drugs means, with respect to an individual, any of the following: (i) Performing any surgery for the purpose of changing the body of such individual to correspond to a sex that differs from their biological sex, including— (I) castration; (II) orchiectomy; (III) scrotoplasty; (IV) vasectomy; (V) hysterectomy; (VI) oophorectomy; (VII) ovariectomy; (VIII) metoidioplasty; (IX) penectomy; (X) phalloplasty; (XI) vaginoplasty; (XII) vaginectomy; (XIII) vulvoplasty; (XIV) reduction thyrochondroplasty; (XV) chondrolaryngoplasty; and (XVI) mastectomy. (ii) Any plastic surgery that feminizes or masculinizes the facial features for the purposes described in clause (i). (iii) Any placement of chest implants to create feminine breasts for the purposes described in clause (i). (iv) Any placement of fat or artificial implants in the gluteal region for the purposes described in clause (i). (v) Administering, supplying, prescribing, dispensing, distributing, or otherwise conveying to an individual medications for the purposes described in clause (i), including— (I) gonadotropin-releasing hormone (GnRH) analogues or other puberty-blocking drugs to stop or delay normal puberty; (II) testosterone or other androgens to biological females at doses that are supraphysiologic to the female sex; and (III) estrogen to biological males at doses that are supraphysiologic to the male sex. (B) Exception Subparagraph (A) shall not apply to the following individuals: (i) An individual with both ovarian and testicular tissue. (ii) An individual with respect to whom a physician has determined through genetic or biochemical testing that the individual does not have normal sex chromosome structure, sex steroid hormone production, or sex steroid hormone action. (iii) An individual experiencing infection, disease, injury, or disorder caused or exacerbated by previous medical procedures as defined in subsection (g)(4)(A). (iv) An individual suffering from a physical disorder, physical injury, or physical illness that would, as certified by a physician, place the individual in imminent danger of death or impairment of a major bodily function unless the procedure is performed. (C) Biological sex For purposes of subparagraph (A), the term biological sex means the indication of male or female sex by reproductive potential or capacity, sex chromosomes, naturally occurring sex hormones, gonads, or internal or external genitalia present at birth. .

November 20, 2024 Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed

tv_txt: I 118th CONGRESS 1st Session H. R. 3887 IN THE HOUSE OF REPRESENTATIVES June 7, 2023 Mr. Crenshaw introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend title III of the Public Health Service Act to reauthorize the program of payments to children’s hospitals that operate graduate medical education programs, and for other purposes.

1. Short title This Act may be cited as the Children’s Hospital GME Support Reauthorization Act of 2023 . 2. Program of payments to children's hospitals that operate graduate medical education programs Section 340E of the Public Health Service Act ( 42 U.S.C. 256e ) is amended— (1) in subsection (a), by striking 2023 and inserting 2028 ; (2) in subsection (b)(3)(D), by inserting and the end of fiscal year 2028, after fiscal year 2022, ; (3) in subsection (e), by adding at the end the following new paragraph: (4) Prohibition on payments to hospitals furnishing gender-affirming care to minors (A) In general Notwithstanding any other provision of this section, no payment may be made under this section to a children’s hospital for a fiscal year (beginning with fiscal year 2024) if, at any point during the preceding fiscal year, such hospital furnished gender-affirming care (as defined in subsection (g)) to an individual under 18 years of age. (B) Special rule for fiscal year 2024 In applying subparagraph (A) with respect to payments described in such subparagraph for fiscal year 2024, the reference to the preceding fiscal year shall be treated as a reference to the period beginning on July 1, 2023, and ending on September 30, 2023 . (C) Rule of construction Nothing in this paragraph shall be construed as prohibiting payments for a fiscal year to a hospital that, during the preceding fiscal year (or, in the case of payments for fiscal year 2024, during the period described in subparagraph (B)), furnished mental or behavioral health services to individuals under 18 years of age for the treatment of gender dysphoria not consisting of gender-affirming care. ; (4) in subsection (f)— (A) in paragraph (1)(A)(vi), by striking 2023 and inserting 2028 ; and (B) in paragraph (2)(F), by striking 2023 and inserting 2028 ; and (5) in subsection (g), by adding at the end the following new paragraph: (4) Gender-affirming care (A) In general Except as provided in subparagraph (B), the term gender-affirming care means, with respect to an individual, any of the following: (i) Performing any surgery for the purpose of changing the body of such individual to correspond to a sex that differs from their biological sex, including— (I) castration; (II) orchiectomy; (III) scrotoplasty; (IV) vasectomy; (V) hysterectomy; (VI) oophorectomy; (VII) ovariectomy; (VIII) metoidioplasty; (IX) penectomy; (X) phalloplasty; (XI) vaginoplasty; (XII) vaginectomy; (XIII) vulvoplasty; (XIV) reduction thyrochondroplasty; (XV) chondrolaryngoplasty; and (XVI) mastectomy. (ii) Any plastic surgery that feminizes or masculinizes the facial features for the purposes described in clause (i). (iii) Any placement of chest implants to create feminine breasts for the purposes described in clause (i). (iv) Any placement of fat or artificial implants in the gluteal region for the purposes described in clause (i). (v) Administering, supplying, prescribing, dispensing, distributing, or otherwise conveying to an individual medications for the purposes described in clause (i), including— (I) gonadotropin-releasing hormone (GnRH) analogues or other puberty-blocking drugs to stop or delay normal puberty; (II) testosterone or other androgens to biological females at doses that are supraphysiologic to the female sex; and (III) estrogen to biological males at doses that are supraphysiologic to the male sex. (B) Exception Subparagraph (A) shall not apply to the following individuals: (i) An individual with both ovarian and testicular tissue. (ii) An individual with respect to whom a physician has determined through genetic or biochemical testing that the individual does not have normal sex chromosome structure, sex steroid hormone production, or sex steroid hormone action. (iii) An individual experiencing infection, disease, injury, or disorder caused or exacerbated by previous gender transition procedures. (iv) An individual suffering from a physical disorder, physical injury, or physical illness that would, as certified by a physician, place the individual in imminent danger of death or impairment of a major bodily function unless the procedure is performed. (C) Biological sex For purposes of subparagraph (A), the term biological sex means the indication of male or female sex by reproductive potential or capacity, sex chromosomes, naturally occurring sex hormones, gonads, or internal or external genitalia present at birth. .